How is Meinian Onehealth creating an inclusive health screening value chain through "AI" breakthroughs?
Under the promotion of the "Healthy China 2030" strategy, health screenings have evolved from simple disease screening tools into core gateways for national health management. Simultaneously, with the development of AI and other new technologies, screening efficiency continues to improve under technological empowerment, and the degree of inclusiveness continues to deepen.
As the industry leader, Meinian Onehealth Healthcare Holdings Co.,Ltd. (002044.SZ) has been sprinting at the forefront of technological innovation since proposing its "All in Digitalization" strategy in 2021, which was upgraded to "All in AI" in 2024. Through AI and other new technologies, the "personalization" level of its health screenings continues to improve, continuously enhancing service "quality-price ratio" at accessible prices while maximizing risk coverage and detection rates.
Official data shows that from 2023 to July this year, Meinian Onehealth has detected 4.3979 million Class A&B important abnormal cases, enabling numerous clients to receive timely hospital diagnosis and treatment for prompt medical intervention.
"Treating Pre-disease" and Identifying "Potential Health Risks"
As an important means of early disease screening, health examinations can transmit health signals through a series of examination indicators, providing early warnings for diseases that may appear in the future, thereby reducing people's life and health risks and property losses.
Take cancer as an example. Cancer has become the disease category with the highest mortality rate among Chinese people. China's tumor registration annual report estimates approximately 4.064 million new cancer cases nationwide each year. More alarmingly, cancer onset age is showing a trend toward younger demographics. The World Health Organization (WHO)'s "2024 Global Cancer Report" shows that new cancer cases among people under 50 globally have surged by 79% over the past 30 years. Data from China's National Cancer Center also shows that in 2022, the cancer incidence rate among China's 35-39 age group increased by nearly 80% compared to 2000, with approximately 300,000 new young cancer patients annually.
The "Expert Consensus on Joint Screening for Common Malignant Tumors (2025 Edition)" initiated by the Tumor Epidemiology Professional Committee of the China Anti-Cancer Association points out that from 2008 to 2021, the 5-year relative survival rates for most common malignant tumors in China showed significant improvement, with lung cancer showing the most remarkable progress. However, compared to European and American countries, except for gastric and esophageal cancers, the 5-year survival rates for most malignant tumor patients in China remain relatively low, mainly because malignant tumor screening in China started relatively late, resulting in a significantly lower proportion of early-stage cancers. For instance, from 2016 to 2017, the overall proportion of Stage I malignant tumors in China was less than 20%, while the proportion of early-stage cancers in the United States during the same period was 35.5%, 15% higher than China.
"Under the multiple influences of population aging and other environmental factors, the incidence of malignant tumors globally is expected to nearly double over the next 30 years. Conducting population screening to improve early detection and diagnosis of malignant tumors is considered one of the most effective measures to reduce tumor disease burden and economic burden," the consensus states. Numerous observational and interventional studies indicate that screening for different types of malignant tumors can reduce malignant tumor mortality by approximately 20%-57%, with conclusions from different periods and studies being almost consistent. Even receiving one-time low-dose CT lung screening or upper gastrointestinal endoscopy screening can significantly reduce population lung cancer mortality by 31% and upper gastrointestinal cancer mortality risk by 57%.
The earlier the discovery, the earlier the treatment, the higher the survival probability. There are many such cases in reality. A "post-90s" Ms. Xie from Shanghai, despite having no symptoms and annual routine gynecological examinations showing "normal" results, had her 2023 early health examination report at a Meinian facility show HPV positive and TCT low-grade lesions, and was diagnosed with cervical cancer at Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital one week later. Ms. Wei, a 38-year-old mother from Hengyang, discovered blood in her urine in September 2023 and through screening at a local Meinian health examination center, an ultrasound examination found an "immovable abnormal mass," escalating the health alert signal from hematuria to tumor within 48 hours. Fortunately, through early screening, both patients began treatment before their diseases developed to irreversible stages, rewriting their destinies.
"Health examinations are significantly meaningful for cancer early screening. Meinian Onehealth particularly emphasizes continuous innovation investment in cancer early screening. When formulating packages, we select preferred screening projects for high-risk tumors based on the latest clinical guidelines and expert consensus," states Meinian Onehealth as the industry leader. The company has developed a cancer management system for ten thousand people, achieving informatization of cancer detection management for ten thousand people. Regional examination branches have introduced closed-loop tracking management requirements for high-risk cancer clients, with customer service doctors promptly reminding clients to go to hospitals for examination and diagnosis, tracking to obtain clients' pathological diagnosis results or discharge summaries as confirmation basis. Through continuous monitoring, high-risk clients receive timely treatment, improving cancer treatment outcomes. From 2023 to July 2025, the group detected 262,800 confirmed cancer cases, with most of these clients being early discoveries receiving timely treatment.
Simultaneously, Meinian Onehealth continuously develops and introduces specialized cancer early screening products to improve cancer and cancer risk detection rates. For example, the company pioneered introducing CT into health examinations in the industry. Currently, CT is the preferred screening project for lung nodules, with lung nodule detection improved from centimeter-level to millimeter-level, greatly improving lung nodule detection rates. The company requires lung nodules to be classified according to international standard LUNG-RADS, achieving precise risk assessment of nodules. Combined with seven types of lung cancer autoantibody detection and imaging results, this greatly improves early lung cancer detection rates. For thyroid and breast nodule screening, the company uniformly requires TI-RADS grading for thyroid nodules and BI-RADS grading for breast nodules, upgrading ultrasound reports from mere nodule descriptions to precise cancer risk assessments, improving early detection rates for thyroid and breast cancers.
Personalized Approach: Enhancing Health Screening "Personalization" Through Technology
Health examinations can use screening methods and technologies to conduct a series of health problem screenings for examinees. However, each individual is a complete independent entity that cannot be exactly the same, and is also affected by economic conditions and other factors, making it difficult to cover all problem screenings. Therefore, to achieve both high-quality screening and cost-effectiveness, "personalization" in health examinations becomes particularly important. In this process, the application of AI and other new technologies is playing an increasingly important role.
From Meinian Onehealth's exploration, first, the company utilizes industry big data analysis to precisely position the high incidence proportions of diseases in different industry populations. This way, when clients choose health examination packages, Meinian Onehealth can use AI data models to customize different package combinations based on questionnaires and industry data, achieving the goal of ensuring quality while allowing clients to enjoy important health problem screening methods.
Second, in product application, Meinian Onehealth selects currently advanced scientific and technological methods, such as "One Scan, Three Checks." "One Scan" refers to one low-dose chest CT scan; "Three Checks" include: first, using AI technology to precisely locate lung nodules, achieving precise millimeter-level nodule screening; second, using AI models to calculate coronary artery calcification scores in the heart area to quantify the degree of coronary artery hardening, thereby determining the possibility of coronary heart disease occurrence, defining moderate and severe calcification as Class C important abnormal results and reminding clients to visit specialist clinics for further imaging diagnosis; third, simulating bone density films to calculate lumbar vertebral body bone conditions, thereby determining osteoporosis conditions for early prevention and intervention. The entire process cleverly integrates AI technology, greatly improving screening efficiency, saving substantial human and material resources, and improving quality-price ratio.
Even post-examination, AI technology still has its applications. Past post-examination management relied on substantial human resources for classification and management, often limited by the number of people, their professional backgrounds, and technical capabilities. Meinian Onehealth uses AI to annotate and identify each abnormal result, conducts comprehensive analysis for risk assessment, then uses digital twins to remind clients of regular follow-ups and precautions. This way, instead of completely relying on people, it depends on digital technology to provide higher cost-effectiveness and more valuable post-examination management services, ensuring synchronous examination and management.
Notably, in recent years, Meinian Onehealth has proposed the "ALL IN AI" strategy, continuously increasing AI research, development, and application efforts, conducting AI empowerment throughout the entire process of health examinations and health management. In personalized examinations, it has also constructed a complete system based on big data and AI technology for automated personalized package generation and intelligent recommendation of in-depth screening projects during examinations, ensuring comprehensiveness and precision of health screening risk assessment.
Generally speaking, package prices determine package project composition to a certain extent. The more package projects, the more comprehensive the health screening coverage, and the higher the disease and health risk detection rate. Under certain package prices, maximizing risk coverage and detection rates has always been Meinian Onehealth's focus, aiming to maximize value for every dollar spent by clients.
For this purpose, Meinian Onehealth pioneered launching an artificial intelligence personalized package automatic generation system—a business development tool that can automatically generate personalized health examination packages based on client budget prices and comprehensive risks, ensuring maximum value of examination projects. During client examinations, upon discovering abnormal signs and symptoms, personalized additional items are adopted for in-depth screening to maximize coverage of client health risks.
In fact, according to data and experience mastered by Meinian Onehealth, projects with high detection rates are actually some routine examination projects with moderate prices, not expensive projects. Meinian Onehealth's "2024 Annual Health Examination Big Data Blue Book" shows that among the top ten indicators with highest detection rates, except for 63.3% lung nodules detected by CT examination (belonging to large equipment projects that are slightly more expensive), the rest including overweight or obesity 51.4%, thyroid nodules 48.7%, fatty liver 43%, breast nodules 37.2%, blood lipid abnormalities 29.2%, Helicobacter pylori infection 25%, hypertension 23.8%, carotid artery plaque 23.8%, and hyperuricemia 20.3% are all routine examination projects. This also shows that price is not the determining factor for disease and health risk detection rates. Even routine examination projects are significantly meaningful for early disease screening. To achieve accurate examination results, the key is selecting personalized projects suitable for oneself to be effective.
Continuous Expansion of Health Examination Industry: AI Empowerment Breaking Traditional Health Management Boundaries
With the arrival of an aging society, public health management awareness is increasingly strengthening, and the health examination industry continues to expand. Chinese Health Statistics Yearbook data shows that from 2012 to 2022, domestic health examination numbers grew from 367 million person-times to 503 million person-times, with a compound annual growth rate of 3.2%. According to "Qianzhan Industry Research Institute" predictions, in the coming years, the health examination market will usher in a rapid growth period, with China's health examination market size expected to exceed 391.6 billion yuan by 2029.
From the policy perspective, in April this year, the Ministry of Commerce, National Health Commission, and 10 other departments jointly issued the "Special Action Plan for Promoting Health Consumption," proposing to strengthen new health service industries, "vigorously develop new service industries such as health examinations, health consulting, and health management, promote innovative health examination products and inspection and testing methods, promote health examination result big data applications, and advance occupational health management."
The rapidly developing market and policy encouragement bring development opportunities for participants while also imposing stricter requirements. Health examination institutions need to consider how to ensure further improvement of health examination service levels and quality while rapidly expanding business, to ensure early screening detection rates and safeguard client health.
As the industry leader, Meinian Onehealth consistently provides inclusive high-standard medical services through nationwide group procurement, efficient operations, AI assistance, and other measures, enabling clients to have "affordable comprehensive examinations" while adhering to "quality-price ratio," allowing more and more enterprises and individuals to spend health budgets where they matter most. In Meinian Onehealth's view, through scientific design, precise design, scale effects, and AI advanced technology, it can directly break the medical industry's "impossible triangle" of "accessibility, low cost, and high quality," ensuring that at accessible prices, it lives up to client trust.
Industry insiders believe that Meinian Onehealth's ability to achieve high quality-price ratio has three main supports: besides the aforementioned artificial intelligence (efficiency improvement and cost reduction), there are also disciplinary capabilities (product strength) and large-scale efficient supply chains.
Based on national standards, Meinian Onehealth not only added some Class A and B important abnormal indicator standards based on actual health examination client situations and established management regulations. Regional health examination centers also added local important abnormal Class C standards according to local disease spectrum conditions, expanding important abnormal management scope and improving management precision. Additionally, Meinian Onehealth continuously improves important abnormal standards and management according to disease spectrum changes and latest clinical guidelines, upgrading management systems and standards three times successively to ensure important abnormal management meets client health management needs.
Data published by Meinian Onehealth shows that from 2022 to 2024, its Class A&B important abnormal detection rates were 5.09%, 7.08%, and 9.52% respectively, with detection rates continuously improving, reflecting Meinian Onehealth's continuous improvement of important abnormal indicators and the continuous enhancement of detection capabilities through introducing specialized and innovative projects. Simultaneously, Meinian Onehealth monitors and assesses the accuracy of important abnormal detection rates to ensure detection accuracy. From 2023 to July 2025, Class A&B important abnormal detections reached 4.3979 million cases. For all clients reaching Class B important abnormalities, branch customer service doctors notify clients within 24 hours to promptly go to hospitals for further diagnosis and treatment, receiving timely medical care.
Currently, Meinian Onehealth has over 600 branches covering more than 290 cities nationwide. With the launch of the ALL IN AI strategy, Meinian Onehealth keeps pace with the latest technological frontiers and has constructed multiple industry-leading AI projects. Through AI empowerment, it achieves leapfrog development in health examination and health management services, truly providing clients with precise, efficient, and personalized health services. For example, China's first private AI health management assistant "Health Xiaomei" released in August 2024, as a classic case of deep integration between AI and medical health, can empower pre-examination, during-examination, and post-examination full-process, high-quality services, providing users with comprehensive, full-lifecycle digital and personalized health management.
Media reports show that as of the end of March 2025, the "Health Xiaomei" intelligent chief physician application has been launched in 109 health examination centers, reviewing and generating over 390,000 health examination reports, with chief physicians' daily processing capabilities significantly improved. Industry insiders believe that with the birth of "Health Xiaomei" as a landmark, under AI empowerment, Meinian Onehealth is breaking traditional health management boundaries and opening a new model of intelligent interaction and precise services.
"Considering the particularity of the health examination industry, which requires substantial labor accumulation including chief physicians and guidance personnel, these operations can achieve efficiency improvements through current AI technology, with potential for short-term cost reduction and efficiency enhancement," points out a research report. From a medium to long-term perspective, AI empowerment is also expected to help Meinian Onehealth activate its C-end ecosystem. The company's strong layout of private domain ecosystems will see further activation of C-end ecosystem functions under AI assistance. Through multi-dimensional report interpretation and personalized intervention, traffic will be directed into the ecosystem. Through the interactivity of personalized health management tools, users will be more willing to frequently use these tools, thereby improving user participation and stickiness in health management. With AI's real-time monitoring and feedback promoting high-frequency usage, this forms high-quality ecosystem operations.
Under the current in-depth advancement of the "Healthy China 2030" strategy, the health examination industry is experiencing profound transformation from "passive screening" to "active intervention," from "standardized services" to "precision medicine." In this historical process, technology is not only a tool for improving medical service efficiency but also the core engine for reconstructing the national health ecosystem. Industry insiders believe that through AI technology empowering full-chain services, data-driven personalized health management, and inclusive models breaking medical resource barriers, the boundary value of the health examination industry is being redefined, providing another possibility for large-scale popularization of health management endeavors.
Comments